Vimarsana
Biggest News Aggregation in the World

Leo Ehrlich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Leo Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Leo Ehrlich Today - Breaking & Trending Today

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024 - Vimarsana News

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024

Published: August 28, 2023

WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to provide shareholders with an update on recent progress in the development of BeaMed’s groundbreaking StingRay Laser System (the “System”). BeaMed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovat

Source: yahoo.com
Related Topics:
United StatesGil ShapiraMoshe EshkolLeo EhrlichIsrael Institute Of TechnologyExchange CommissionInnovation Pharmaceuticals IncRambam Health Care CampusMassachusetts Institute Of TechnologyNewmediawire Innovation PharmaceuticalsInnovation PharmaceuticalsMed TechnologiesStingray Laser SystemBeamed SystemTechnion Israel InstituteRambam Health CareKey Opinion LeadersChief Executive OfficerStingray SystemMassachusetts InstituteLooking StatementsPrivate Securities Litigation Reform ActT Beamed TechnologiesThe CompanyProduct Development
Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform - Vimarsana News

Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform

Published: September 13, 2022

WAKEFIELD, MA / ACCESSWIRE / September 13, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today updated shareholders on recent progress by BT

Source: finanznachrichten.de
Related Topics:
United StatesLeo EhrlichExchange CommissionInnovation Pharmaceuticals IncBt Beamedical Technologies LtdSqualus Medical LtdInnovation PharmaceuticalsMedical TechnologiesFortec MedicalLooking StatementsPrivate Securities Litigation Reform ActStingray System
Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox - Vimarsana News

Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox

Published: August 5, 2022

WAKEFIELD, MA / ACCESSWIRE / August 5, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's defensin-mimetic

Source: finanznachrichten.de
Related Topics:
United StatesLeo EhrlichCenters For DiseaseInnovation Pharmaceuticals IncUs Department Of HealthHuman ServicesNational Institutes Of HealthNational Institute Of AllergyWorld Health OrganizationExchange CommissionStrategic National StockpileInnovation PharmaceuticalsPublic Health Emergency Of International ConcernNational InstitutesNational InstituteInfectious DiseasesChief Executive OfficerEmergency DashboardDisease ControlPublic Health EmergencyInternational ConcernExpanded AccessVaccinia VirusEczema VaccinatumFuture Considerations
Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium - Vimarsana News

Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium

Published: June 28, 2022

Research was performed by scientists at George Mason University's Center for Infectious Disease Research (formerly NCBID)WAKEFIELD, MA / ACCESSWIRE / June 28, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX)

Source: finanznachrichten.de
Related Topics:
United StatesLeo EhrlichUs Department Of DefenseInnovation Pharmaceuticals IncCompany PhaseGeorge Mason University CenterDevelopment Of New Front Line Therapies ToHealth System Research SymposiumInfectious Disease ResearchExchange CommissionConvention CenterInnovation PharmaceuticalsGeorge Mason UniversityPoster PresentationGaylord Palms ResortHost Defense Peptide MimeticNew Front Line TherapiesTreat Endemic Viral DiseasesLooking StatementsPrivate Securities Litigation Reform ActStingray System
Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology - Vimarsana News

Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology

Published: June 15, 2022

Innovation Pharmaceuticals acquires a minority ownershipSqualus has invented and is developing a leading-edge image guided surgical laser platform for treating previously inoperable cases of epilepsy and

Source: finanznachrichten.de
Related Topics:
United StatesLeo EhrlichMoshe EshkolGil ShapiraExchange CommissionInnovation Pharmaceuticals IncMassachusetts Institute Of TechnologyEuropean Union Ce MarkDrug AdministrationInnovation PharmaceuticalsIsrael Based Squalus MedicalStingray Laser SystemStingray SystemChief Executive OfficerEuropean UnionMassachusetts InstituteLooking StatementsPrivate Securities Litigation Reform Act